Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 6/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.52 |
| ▸ | CDC42BPB | Q9Y5S2 | 6/20 | 0.52 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.46 |
| ▸ | TPX2 | Q9ULW0 | 2/20 | 0.46 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.45 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26174643 | 0.84 | ROCK2 (0.56) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL16835899 | 0.80 | ROCK2 (0.56) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL26174617 | 0.79 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL30400127 | 0.78 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL26174642 | 0.78 | ROCK2 (0.53) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL16854189 | 0.78 | ROCK2 (0.62) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL16835978 | 0.78 | ROCK2 (0.62) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL26174628 | 0.78 | ROCK2 (0.52) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL30400624 | 0.78 | ROCK2 (0.52) | ROCK2ROCK1CDC42BPBAURKAAURKB | |
| SCHEMBL26174644 | 0.78 | ROCK2 (0.52) | ROCK2ROCK1CDC42BPBAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | claimed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | claimed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | claimed |
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3083618-B1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695171-B2 | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015092592-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002000-A1 | NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-b]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-c]PYRIDAZINES AS LRRK2 INHIBITORS | LRRK2, PARK7, BRCA1 | ROCK2 505/4885ROCK1 472/4885CDC42BPB 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.